ProKidney Corp. (NASDAQ: PROK) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT PROKIDNEY CORP.

ProKidney Corp. (NASDAQ: PROK)
Listen to this Section


$1.84
+0.1050 ( +6.07% ) 440.7K

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

Market Data


Open $1.84
Previous Close $1.73
Volume 440.7K
Market Cap $355.00M
Day Range $1.74 - $1.87
52 Week Range $0.54 - $7.13
Shares Outstanding 205.20M
Change % +6.07%
Net Change ▲ 0.1050
Insider Ownership -0.05%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2022
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 30,782,379.00

Date Type Amount Purchased Purchaser
2024-08-02 Sale -81928.00 Girolamo Todd C
2024-07-29 Sale -826.00 Weber Darin J.
2024-06-25 Buy 8264462.00 Control Empresarial de Capitales S.A. de C.V.
2024-06-20 Sale -17238.00 Weber Darin J.
2024-06-14 Buy 22617909.00 Legorreta Pablo G.

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jun 02, 2025

Latest News


× Before browsing our site, please accept our cookies policy